Skip to main content
    E

    Elevance Health Inc (ELV)

    Official site

    HEALTHCARE • HEALTHCARE PLANS • NYSE

    $446.42
    +16.73 (+3.89%)

    Market Cap: $92.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Elevance Health Inc (ELV) Earnings: Report Dates and Results

    Updated Oct 21, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Elevance Health (ELV) is expected to report earnings on Jan 26, 2027. In the quarter ended Sep 30, 2026, Elevance Health reported EPS of $6.99, above the $4.66 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +5.98%
    Streak
    5 Q

    Upcoming Estimates

    Reports Jan 26, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.08
    Range$1.61 - $3.38
    23 analysts
    Revenue Consensus
    $49.74B
    Range$46.08B - $52.81B
    19 analysts
    Reports Apr 20, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$12.32
    Range$8.69 - $13.23
    14 analysts
    EPS Revisions
    8
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$12.03+2.4%
    60d ago$12.03+2.4%
    30d ago$12.12+1.6%
    7d ago$12.14+1.4%
    Current$12.32
    Revenue Consensus
    $50.06B
    Range$49.26B - $51.06B
    7 analysts

    Next Report

    ELV has an expected report date of Jan 26, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 37.5% below the $3.33 reported for the quarter ended Dec 31, 2025.

    ELV Earnings Call

    The latest ELV earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ELV beat 35, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $51.43B, up 1.4% from $50.71B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$6.99$4.66$4.55 - $4.99+50.00%Beat+15.9%193 up, 1 downOct 21, 2026$51.43B
    Jun 30, 2026$7.45$6.18$6.06 - $6.73+20.55%Beat-15.7%200 up, 0 downJul 15, 2026$50.47B
    Mar 31, 2026$12.58$10.81$6.53 - $11.28+16.37%Beat+5.1%202 up, 1 downApr 22, 2026$50.18B
    Dec 31, 2025$3.33$3.09$2.85 - $3.32+7.77%Beat-13.3%201 up, 2 downJan 28, 2026$49.75B
    Sep 30, 2025$6.03$4.94$4.47 - $5.94+22.06%Beat-28.0%202 up, 2 downOct 21, 2025$50.71B
    Jun 30, 2025$8.84$8.92$8.70 - $9.98-0.90%Miss-12.6%190 up, 7 downJul 17, 2025$49.78B
    Mar 31, 2025$11.97$11.48$10.58 - $11.85+4.27%Beat+12.5%189 up, 0 downApr 22, 2025$48.89B
    Dec 31, 2024$3.84$3.85$3.77 - $3.97-0.26%Miss-31.7%170 up, 1 downJan 23, 2025$45.44B
    Sep 30, 2024$8.37$9.65$9.17 - $10.19-13.26%Miss-6.9%191 up, 1 downOct 17, 2024$45.15B
    Jun 30, 2024$10.12$10.01$9.82 - $10.27+1.10%Beat+11.9%200 up, 1 downJul 17, 2024$43.65B
    Mar 31, 2024$10.64$10.53$10.17 - $11.07+1.04%Beat+12.5%182 up, 0 downApr 18, 2024$42.58B
    Dec 31, 2023$5.62$5.59$5.51 - $6.48+0.54%Beat+7.5%142 up, 0 downJan 24, 2024$42.65B
    Sep 30, 2023$8.99$8.46$8.07 - $8.65+6.26%Beat+19.4%182 up, 0 downOct 18, 2023$42.85B
    Jun 30, 2023$9.04$8.78$8.45 - $8.99+2.96%Beat+12.4%200 up, 1 downJul 19, 2023$43.67B
    Mar 31, 2023$9.46$9.28$8.96 - $9.45+1.94%Beat+14.7%192 up, 1 downApr 19, 2023$42.17B
    Dec 31, 2022$5.23$5.19$5.12 - $5.27+0.77%Beat+1.8%200 up, 2 downJan 25, 2023$39.93B
    Sep 30, 2022$7.53$7.15$6.83 - $7.26+5.31%Beat+10.9%192 up, 3 downOct 19, 2022$39.94B
    Jun 30, 2022$8.04$7.74$7.38 - $7.92+3.88%Beat+14.4%202 up, 0 downJul 20, 2022$38.63B
    Mar 31, 2022$8.25$7.83$7.26 - $8.31+5.36%Beat+17.7%193 up, 0 downApr 20, 2022$38.09B
    Dec 31, 2021$5.14$5.12$4.99 - $5.68+0.39%Beat+102.4%220 up, 0 downJan 26, 2022$36.58B
    Sep 30, 2021$6.79$6.37$5.81 - $6.93+6.59%Beat+61.7%20N/AOct 20, 2021$35.82B
    Jun 30, 2021$7.03$6.34$6.12 - $6.55+10.88%Beat-23.6%21N/AJul 21, 2021$33.85B
    Mar 31, 2021$7.01$6.47$5.82 - $7.83+8.35%Beat+8.2%18N/AApr 21, 2021$32.38B
    Dec 31, 2020$2.54$2.53$2.40 - $3.01+0.40%Beat-34.5%19N/AJan 27, 2021$31.82B
    Sep 30, 2020$4.20$4.18$3.77 - $4.71+0.48%Beat-13.8%22N/AOct 28, 2020$31.16B
    Jun 30, 2020$9.20$8.58$6.04 - $9.31+7.23%Beat+98.3%22N/AJul 29, 2020$29.26B
    Mar 31, 2020$6.48$6.44$6.25 - $7.12+0.62%Beat+7.5%17N/AApr 29, 2020$29.62B
    Dec 31, 2019$3.88$3.89$3.83 - $4.07-0.26%Miss+59.0%23N/AJan 29, 2020$27.41B
    Sep 30, 2019$4.87$4.82$4.64 - $5.03+1.04%Beat+27.8%22N/AOct 23, 2019$26.67B
    Jun 30, 2019$4.64$4.62$4.50 - $4.86+0.43%Beat+9.2%21N/AJul 24, 2019$25.47B
    Mar 31, 2019$6.03$5.90$5.05 - $6.87+2.20%Beat+11.5%21N/AApr 24, 2019$24.67B
    Dec 31, 2018$2.44$2.20$2.13 - $2.35+10.91%Beat+89.1%21N/AJan 30, 2019$23.37B
    Sep 30, 2018$3.81$3.70$3.41 - $4.07+2.97%Beat+43.8%21N/AOct 31, 2018$23.25B
    Jun 30, 2018$4.25$4.18$3.75 - $4.40+1.67%Beat+26.1%20N/AJul 25, 2018$22.94B
    Mar 31, 2018$5.41$4.89$4.58 - $5.22+10.63%Beat+15.6%18N/AApr 25, 2018$22.54B
    Dec 31, 2017$1.29$1.27$1.16 - $1.51+1.57%Beat-26.7%20N/AJan 31, 2018$22.68B
    Sep 30, 2017$2.65$2.40$2.24 - $2.57+10.42%Beat+8.2%15N/AOct 25, 2017$22.43B
    Jun 30, 2017$3.37$3.24$2.90 - $3.48+4.01%Beat+1.2%19N/AJul 26, 2017$22.41B
    Mar 31, 2017$4.68$3.81N/A+22.83%Beat+35.3%N/AN/AApr 26, 2017$22.53B
    Dec 31, 2016$1.76$1.76N/A0.00%In line+54.4%N/AN/AFeb 1, 2017$21.71B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $30.17, down 8.5% from the year before. It was $11.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$30.17-8.5%
    Dec 31, 2024$32.97-0.4%
    Dec 31, 2023$33.11+14.0%
    Dec 31, 2022$29.05+11.9%
    Dec 31, 2021$25.97+15.8%
    Dec 31, 2020$22.42+15.4%
    Dec 31, 2019$19.42+22.1%
    Dec 31, 2018$15.91+32.7%
    Dec 31, 2017$11.99+9.0%
    Dec 31, 2016$11.00N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,700 words across 23 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,74823
    2026Q2Jun 30, 20267,42822
    2026Q1Mar 31, 20267,14424
    2025Q4Dec 31, 20252,2959
    2025Q3Sep 30, 20259,08821
    2025Q2Jun 30, 20257,60623
    2025Q1Mar 31, 20256,90622
    2024Q4Dec 31, 20248,71623

    2026Q3 Earnings Call

    Opening remarks

    Nathan Rich Vice President of Investor Relations Good morning, and welcome to Elevance Health's third quarter 2026 earnings conference call. My name is Nathan Rich, Vice President of Investor Relations. With us today on the earnings call are Gail Boudreaux, President and CEO, Mark Kaye, our CFO, Felicia Norwood, our Chief Health Benefits Officer, and Morgan Kendrick, President of our Commercial Health Benefits business. Gail will highlight our third quarter performance and discuss the progress we're making on our strategic priorities. Mark will then discuss our financial results and the drivers supporting our earnings outlook in greater detail. After our prepared remarks, the team will be available for a question-and-answer session. During the call, we will reference certain non-GAAP financial measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website, elevancehealth.com. We will also be making forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Elevance Health. These risks and uncertainties may cause actual results to differ materially from our current expectations, and we advise listeners to carefully review the risk factors discussed in today's press release and in our quarterly filings with the SEC. I will now turn the call over to Gail.

    Gail Boudreaux President and CEO Good morning, and thank you for joining us. Elevance Health delivered strong third quarter results, with Medicaid, Medicare Advantage, and Individual ACA each contributing to our better-than-expected performance. These results reflect focused execution across the enterprise. They support a higher earnings outlook for 2026 and increase our confidence in the sustainability of our performance entering 2027. We are revising our 2026 adjusted diluted earnings per share guidance to at least $29, reflecting operating outperformance as well as favorable non-operating items. More importantly, we're raising our 2026 earnings baseline to at least $26.75. That increase reflects better underlying results and greater confidence in the durability of that performance. From this higher baseline, we remain confident in our ability to deliver at least 12% adjusted diluted earnings per share growth in 2027. We expect that growth to be driven by continued margin improvement in Health Benefits, broader adoption of Carelon's value-based solutions, and greater operating efficiency across the enterprise. We are bringing together the scale and local presence of our Health Benefits business with Carelon's clinical and operational expertise to improve outcomes and make care more affordable. As we extend these solutions across our health plans and to external clients, we expect to improve medical cost management, increase operating leverage, and deliver greater value for those we serve. We are already seeing measurable results.

    Frequently Asked Questions About ELV

    When is Elevance Health's next earnings date?

    Elevance Health's next earnings report is expected for Jan 26, 2027.

    Did ELV beat earnings estimates last quarter?

    Yes. Elevance Health reported EPS of $6.99 for the quarter ended Sep 30, 2026, above the $4.66 estimate, a 50.00% surprise.

    What EPS do analysts expect from ELV next quarter?

    The consensus EPS estimate for Elevance Health for the quarter ending Dec 31, 2026 is $2.08 from 23 analysts, with estimates from $1.61 to $3.38.

    How often does ELV beat earnings estimates?

    Elevance Health beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +14.98%.